Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

339.25 +3.06 (+0.91%)

Streaming Delayed Price Updated: 9:51 AM EST, Feb 23, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	34,767
Open	335.73
Bid (Size)	338.70 (160)
Ask (Size)	339.77 (40)
Prev. Close	336.19
Today's Range	334.00 - 341.38
52wk Range	205.87 - 495.55
Shares Outstanding	118,847,693
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference

Today 10:00 EST

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

February 19, 2026

Via Investor Brand Network

Performance

YTD	-15.2%	-15.2%
1 Month	-5.2%	-5.2%
3 Month	-21.9%	-21.9%
6 Month	-23.5%	-23.5%
1 Year	+36.3%	+36.3%

More News

Why Alnylam Pharmaceuticals Stock Was Soaring on Monday ↗

February 17, 2026

Via The Motley Fool

Alnylam Pharmaceuticals (NASDAQ:ALNY) Fits the 'Affordable Growth' GARP Profile ↗

January 28, 2026

Via Chartmill

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): A GARP Candidate with Strong Growth and Fair Valuation ↗

January 06, 2026

Via Chartmill

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

February 19, 2026

From BioMedWire

Via GlobeNewswire

Why Alnylam Pharmaceuticals Stock Slipped Today ↗

February 12, 2026

Via The Motley Fool

Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance

February 12, 2026

Via Finterra

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress

February 12, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results

January 29, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Should You Buy Alnylam Pharmaceuticals Before Feb. 12? ↗

January 28, 2026

Via The Motley Fool

Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact

January 11, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500

January 02, 2026

Via PredictStreet

Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics

December 17, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027

December 11, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): A Prime GARP Candidate for Affordable Growth ↗

December 10, 2025

Via Chartmill

Is Alnylam Pharmaceuticals a Millionaire Maker? ↗

December 07, 2025

Via The Motley Fool

Alnylam Pharmaceuticals Announces Changes to Board of Directors

December 03, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint ↗

December 02, 2025

Via Investor's Business Daily

Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker ↗

November 12, 2025

Via Benzinga

Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money ↗

November 11, 2025

Via The Motley Fool

Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds

November 10, 2025

Via MarketMinute

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

November 08, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today ↗

November 07, 2025

Via Benzinga

Frequently Asked Questions

Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?

Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market

What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?

The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 339.25

When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 02/23/26 09:51 AM ET

What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 40.32B

How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?

Alnylam Pharmaceuticals, Inc. - Common Stock has 40B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.